Annovis Bio, Inc. (ANVS) · Oct 30, 2026 · Delisting
NYSE deficiency notice — $48.4M 30-day market cap vs $50M threshold; $4.3M stockholders’ deficit
Annovis received an NYSE deficiency notice as its Phase 3 biotech program approaches pivotal Alzheimer’s data and NDA preparation.
Annovis is a capital-constrained, Phase 3 biotech moving its lead drug buntanetap toward pivotal Alzheimer’s data and eventual NDA preparation; its pivotal Alzheimer’s trial reached full enrollment in July, and the company has since been preparing for the next development milestone.
The filing adds a real listing and financing constraint. Annovis received an NYSE notice because its 30-trading-day average market capitalization fell below the $50 million requirement while stockholders’ equity was also below $50 million. The filing gives the shortfall as approximately $48.4 million of average market capitalization and a $4.3 million stockholders’ deficit. 〔0〕
| Metric | Filing figure | Standard / deadline |
|---|---|---|
| 30-day average market capitalization (Notice) | $48.4M | $50M minimum |
| Stockholders’ equity (June 30, 2026) | $(4.3)M | Less than $50M |
| Compliance plan | Within 45 days | 9-month cure period |
| Abnormally low trading level | — | Generally below $0.10 |
The immediate consequence is procedural, not an operating shutdown. The stock remains listed during the cure process if the NYSE accepts the company’s plan, but the added “.BC” designation publicly flags the deficiency. 〔1〕
The bigger issue is capital flexibility while the company is approaching a costly clinical and regulatory stretch. The filing says operations and reporting obligations continue normally, but restoring equity and market capitalization may require actions that affect financing terms, ownership, or the timeline for advancing buntanetap. The company has 45 days from the October 29 notice to submit a plan, and the NYSE can begin delisting proceedings if the plan is late, rejected, or ultimately unsuccessful. 〔2〕
Bottom line: This does not halt Annovis’s Phase 3 program today, but it turns a visible financial weakness into a formal exchange-compliance problem. The next meaningful test is whether the NYSE accepts a credible plan to restore compliance before pivotal data and NDA work demand more capital. Cite filing: 〔3〕
NYSE compliance plan submission, by December 13, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!